Saturday, September 10, 2022 3:29:12 PM
Manufacturing, manufacturing, and more manufacturing
Per your comment
"Professionals given incomplete data without the relevant background can be mislead like shareholders. How many professionals that don't have conflict of interest, have had the full story of the manipulated protocol/SAP, the confounding of the naïve OS, the post hoc data dredging of the recurrent GBM data."
As a professional, scientist, researcher, business executive, with well over 45+ years of product design and development, I am grateful to have successfully created multiple products to market that are now worth well over billions of dollars. My experience and relative background have spanned every aspect of the entire product design and development process. I would have not invested in NWBO if I knew that the data was skewed, manipulated, and other misleading fabrications by confounded outsiders trying to spin bogus information.
The bottom line, many doctors, scientist, professionals and present their case to support NWBO and the fact of the matter is that they are extremely impressed with the OS results not the superficial PFS statistical estimations, but the real results as already present as well as posted. Furthermore, I will not address the FDA at this point but understand the process for approval by the FDA and other agencies that require manufacturing stability, volume production capability and knowing that NWBO has a solid team in place to back up their claims. Not to mention the fact that there is a vast array of external manufacturing partnerships that are involved and support NWBO. Including, multiple university support, a host of doctors, scientist, and professionals that are all worthy. NWBO is moving forward and that is all that matters, IMPO.
Per your comment
"Professionals given incomplete data without the relevant background can be mislead like shareholders. How many professionals that don't have conflict of interest, have had the full story of the manipulated protocol/SAP, the confounding of the naïve OS, the post hoc data dredging of the recurrent GBM data."
As a professional, scientist, researcher, business executive, with well over 45+ years of product design and development, I am grateful to have successfully created multiple products to market that are now worth well over billions of dollars. My experience and relative background have spanned every aspect of the entire product design and development process. I would have not invested in NWBO if I knew that the data was skewed, manipulated, and other misleading fabrications by confounded outsiders trying to spin bogus information.
The bottom line, many doctors, scientist, professionals and present their case to support NWBO and the fact of the matter is that they are extremely impressed with the OS results not the superficial PFS statistical estimations, but the real results as already present as well as posted. Furthermore, I will not address the FDA at this point but understand the process for approval by the FDA and other agencies that require manufacturing stability, volume production capability and knowing that NWBO has a solid team in place to back up their claims. Not to mention the fact that there is a vast array of external manufacturing partnerships that are involved and support NWBO. Including, multiple university support, a host of doctors, scientist, and professionals that are all worthy. NWBO is moving forward and that is all that matters, IMPO.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
